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Background: Plasma B-type natriuretic peptide (BNP) levels are increased in patients with heart failure and are
negatively correlated with body mass index (BMI). However, the effects of BMI in decreasing the plasma BNP
levels have not been examined among patients in different BMI categories.
Methods: 676 consecutive patients were divided into groups according to their BMI and heart failure grade. We
examined the relationship between plasma BNP level and BMI in patients who were admitted to our cardiovas-
cular unit.
Results: There were signiﬁcant differences, not only in the mean plasma BNP level, but also in the distribution
pattern of the plasma BNP levels between the low- and high-BMI groups. The plasma BNP levels were negatively
correlatedwith the BMI values in each group stratiﬁed by the New York Heart Association (NYHA) class (I, II and
III + IV); however, the regression line was steeper for the higher NYHA classiﬁcation, and the plasma BNP levels
remained low in patients with a high BMI, even in the NYHA III + IV group.
Conclusions: BMI is a signiﬁcant factor that reduces the plasma BNP level. This impact is signiﬁcantly increased in
patients with a high BMI, even among those with a worsening severity of heart failure.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
It is widely recognized that plasma B-type natriuretic peptide (BNP)
levels are elevated in patients with heart failure. BNP is a cardiac hor-
mone [1] with a wide range of potent biological effects, including
vasodilation, natriuresis and inhibition of the renin–angiotensin–
aldosterone (RAA) and sympathetic nervous systems [2–6]. Measure-
ment of the plasma BNP level is very useful for the early detection of
heart failure, for estimating the severity of heart failure and also for
predicting the patient prognosis [7–18].
The plasma BNP levels of obese patients are often lower than those
of non-obese patients with heart failure, and the body mass index
(BMI) was identiﬁed to be a signiﬁcant factor determining the plasma
BNP level in a previous study [19]. We also have reported that a high
BMI is associated with a decrease in the plasma BNP level, whereas
renal dysfunction and advanced age increase the BNP levels [20,21].
Nonetheless, it is still unclear how large the impact of the BMI is on
the plasma BNP levels. To investigate the precise relationship between
plasma BNP levels and BMI, we ﬁrst examined the patterns ofpartment of Internal Medicine,
bashi, Minato-ku, Tokyo 105-
3.
nd Ltd. This is an open access article udistribution of the plasma BNP levels according to the BMI and then
also examined the impact of the BMI on the plasma BNP levels in rela-
tion to the severity of heart failure as assessed by the New York Heart
Association (NYHA) functional classiﬁcation. Finally, we evaluated the
prognostic impact of the BMI and the plasma BNP levels in this study
population, describing our understanding of the features underlying
the obesity paradox [22–24].
2. Methods
2.1. Study population
This study comprised 676 consecutive patients who were all admit-
ted to the cardiovascular unit of The Jikei University Hospital for any
reason between April 2008 and February 2010. The plasma BNP levels
were measured at admission in patients suspected to have heart failure
andwhowere in stable conditionwithin 48 h after admission. The study
protocol was approved by the ethics committee of The Jikei
University School of Medicine (license number, 23-298 [6759]).
2.2. Blood sampling and measurement of the plasma BNP levels
A central laboratory for biological analyses was used by our hospital.
Whole blood (5 mL) was collected in tubes containing potassium EDTAnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
The characteristics of all patients.
Characteristics Overall (n = 676)
Gender M/F 529/147
Age (years old) 65.2 ± 13.2
BMI (kg/m2) (range) 23.8 ± 3.5 (15.2–40.8)
Creatinine (mg/dL) 1.44 ± 2.08
CRP (mg/dL) 1.45 ± 4.35
BNP (pg/mL) 283.7 ± 642.4, #51.0 [19.2–208.9]
NYHA class (I/II/III/IV) 1.44 ± 0.84 (498/88/58/32)
LVEF (%) 55.0 ± 15.5
Underlying cardiovascular disease
[number (%)]
Ischemic heart disease 293 (43.3)
Congestive heart failure 178 (26.3)
Arrhythmia 162 (23.9)
Cardiomyopathy 10 (1.5)
Valvular disease 6 (0.9)
Other heart diseases 27 (3.9)
Hypertension 427 (67.5)
Type 2 diabetes mellitus 230 (36.5)
Dyslipidemia 360 (59.7)
Renal dysfunction
(eGFR b 60 mL/min/1.73 m2)
264 (39.1)
BMI, body mass index; BNP, B-type natriuretic peptide; eGFR, estimated glomerular
ﬁltration rate; CRP, C-reactive protein; NYHA class, NewYork Heart Association functional
classiﬁcation; LVEF, left ventricular ejection fraction.
Mean ± SD; #, median [interquartile range].
There was no statistically signiﬁcant difference between the groups without explanatory
notes.
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after admission by an enzyme-linked immunosorbent assay (non-ex-
tracted) using an antibody against human BNP (Shionogi Co. Ltd.,
Tokyo, Japan). The other serum biochemical analyses of the following
parameters were performed in a central laboratory at our hospital
during the study.
2.3. Grouping of patients by BMI and grade of heart failure
Based on their height andweight on admission, the bodymass index
(BMI) of the patients was calculated as the bodyweight (kg) divided by
the square of the height (m2). The patients were divided equally into
two, three or four groups according to the BMI levels, or were divided
into three groups according to their grade of heart failure as assessed
by the New York Heart Association (NYHA) functional classiﬁcation.
The heart failure was diagnosed according to the guidelines for the
treatment of heart failure [25,26], and the patients who had symptoms
of heart failure were checked by several examinations (blood gas anal-
ysis, blood sampling, electrocardiogram, plain chest radiograph, echo-
cardiogram) and were ﬁnally admitted to our hospital based on the
ﬁndings of these examinations. Each group was statistically analyzed
with regard to the relationship between the plasma BNP levels and
the frequency distributions of the BMI.
2.4. Doppler echocardiograms and other measurements
Doppler echocardiographywas performed by expert cardiologists in
this study, and echocardiograms were obtained for all patients. The left
ventricular ejection fraction (LVEF) was measured in the M-mode
(Teichholz formula) and/or by quantitative 2D (biplane modiﬁed
Simpson's rule) methods for each subject. The correlation among the
methods was excellent (n = 380, r2 = 0.701, p b 0.001).
2.5. Deﬁnition of renal dysfunction by the estimated glomerular ﬁltration
rate (eGFR)
Patients with renal dysfunction were deﬁned as those having an es-
timated glomerular ﬁltration rate (eGFR) of b60 mL/min/1.73m2 at ad-
mission according to the guidelines of the Japanese Society of
Nephrology. We calculated the eGFR according to the Modiﬁcation of
Diet in Renal Disease (MDRD) Study equation [27] shown below, with
coefﬁcients modiﬁed for Japanese patients [28]:
eGFR mL=min=1:73 m2
 
¼ 194 age−0:287  Scr−1:094 and 0:739 for femalesð Þ:
2.6. Statistical analysis
Continuous variableswere expressed as themeans± standard devi-
ation (SD) or medians [interquartile range: IQR]. The correlation be-
tween the plasma BNP levels and BMI values was expressed as
Pearson's and Spearman's correlation coefﬁcients, and to adjust for
other confounding variables, a multiple linear regression analysis was
performed when multiple values were compared. In the multivariate
analysis, logarithmic conversion was performed on the BNP values be-
cause they were not normally distributed. Two groups or conditions
were compared using the Mann–Whitney U test or chi-square test as
appropriate, and the frequency distributions of these groups were com-
pared using the F test in the statistical analyses.
To examinewhether the NYHA functional classiﬁcation had a statis-
tically signiﬁcant impact on the relationship between the logarithmic
plasma BNP levels and BMI in each NHYA functional classiﬁcation, a
multiple linear regression analysis was employed in which the depen-
dent variable was the logarithmic plasma BNP level and the explanatory
variables were the BMI, the NYHA functional classiﬁcation and theinteraction term between the BMI and NYHA functional classiﬁcation
[BMI times (×) NYHA functional classiﬁcation] [29]. We present the
scatter plots byNYHA functional classiﬁcation to illustrate themodiﬁca-
tion of the relationship between the logarithmic plasma BNP levels and
the BMI.
To evaluate the prognostic impact of the BMI and the plasma BNP
levels, the main outcome measures were deﬁned as the major adverse
cardiovascular events (MACE) deﬁned as a composite of cardiovascular
death, non-fatal myocardial infarction, unstable angina, heart failure,
stroke and other cardiovascular events requiring hospitalization. The
potential prognostic factors for this main outcome were assessed by
Kaplan–Meier curves, log-rank test and Cox proportional hazard
models. We performed an analysis by dividing patients into two groups
using 200 pg/mL as the cut-off value for the plasma BNP level, which
was previously reported to be the threshold value of plasma BNP for
predicting the prognosis of a patient [13]. In addition, the patients
were divided into two groups (bipartite, BMI values b or ≥ the median
value of BMI) according to the BMI levels; and the clinical outcomes
were assessed by generating a Kaplan–Meier curve for the MACE in
each bipartite group. All statistical analyses were performed using the
SPSS Statistics software program (version 21 J, IBM Japan, Tokyo,
Japan), and differences were considered to be statistically signiﬁcant
for the two-tailed and p-values b 0.05.3. Results
3.1. Characteristics of the study population
The baseline characteristics of the overall population (n= 676) and
each BMI group in the present study are shown in Table 1. The underly-
ing diseases were ischemic heart disease in 293 patients (43.3%), con-
gestive heart failure in 178 patients (26.3%), arrhythmias in 162
patients (23.9%), cardiomyopathy in 10 patients (1.5%), valvular disease
in six patients (0.9%) andother diseases in 27 patients (3.9%). Renal dys-
function (eGFR b 60 mL/min/1.73 m2) was noted in 264 patients
(39.1%) in this population.
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There was a signiﬁcant correlation between the BMI and the plasma
BNP levels (n=676, r2= 0.0204, p b 0.001; using Pearson's correlation
coefﬁcient and r2 = 0.0412, p b 0.001; non-parametric Spearman's
correlation coefﬁcient).
3.3. Multivariable predictors of the plasma BNP levels
The multivariable regression analysis identiﬁed BMI as an
independent negative correlate of the logarithmic plasma BNP levels
(p b 0.001, standard β-coefﬁcient−0.104; Table 2). Other independent
factors including female gender, age, serum creatinine level and NYHA
classiﬁcation were also signiﬁcantly associated with the logarithmic
plasma BNP levels as independent positively-correlated factors.
3.4. Grouping of the BMI classiﬁcation and the distribution patterns among
the sub-divided patients
The patients were divided into two, three or four groups (bipar-
tite, tertile or quartile groups) according to their BMI in order to
compare the distribution patterns of the plasma BNP levels among
the sub-divided patients (only the detailed data for the bipartite
groups are shown): low BMI (range, 15.2–23.6; mean ± SD, 21.1 ±
1.9) group (n = 338, median and IQR of plasma BNP level, 66.5
[26.1–361.9] pg/mL), high BMI (23.7–40.8; 26.5 ± 2.7) group (n =
338, median and IQR of plasma BNP level, 34.7 [15.3–129.0] pg/mL).
F test was performed to compare the frequency distributions and
Mann–Whitney U test was performed for comparison of the average
plasma BNP levels in each group. As a result, not only the Mann–
WhitneyU test but also the F testwas found to be statistically signiﬁcant
for the comparison between the low BMI group and the high BMI group,
as shown in Fig. 1. The medianwas shifted to a lower value and the dis-
tribution patterns become narrower as the BMI increased.
3.5. Inﬂuence of the NYHA heart failure classiﬁcation on the relationship
between BMI and plasma BNP levels
The plasma BNP level increased depending on the severity of heart
failure (median and IQR of the plasma BNP, 32.8 [14.9–73.6] pg/mL in
the NYHA class I group; 396.0 [115.4–769.3] pg/mL in the NYHA class
II group; 927.1 [385.4–1697.4] pg/mL in the NYHA class III + IV
group; p b 0.001 between NYHA class I and class II, and between
NYHA class I and class III + IV). A signiﬁcant correlation was observed
between the BMI and the plasma BNP levels in all three groups of pa-
tients stratiﬁed by heart failure classiﬁcation, as shown in Fig. 2. The
negative correlation between BMI and plasma BNP level seemed to be
stronger as the degree of heart failure increased. In order to conﬁrm
the statistical signiﬁcance of differences among these regression lines,
we performed a subsequent analysis.
A multiple linear regression analysis was performed to determine
whether the plasma BNP levels have a statistically signiﬁcant impactTable 2
The results of the multiple regression analysis to identify the clinical factors inﬂuencing






Gender 0.001 0.088 0.155 0.060, 0.249
Age b0.001 0.204 0.011 0.008, 0.014
BMI b0.001 −0.104 −0.022 −0.032,−0.011
Creatinine b0.001 0.156 0.054 0.036, 0.073
NYHA class b0.001 0.574 0.496 0.449, 0.542
Constant b0.001 0.774 0.420, 1.127
BMI, body mass index; BNP, B-type natriuretic peptide; NYHA class, New York Heart
Association functional classiﬁcation.on the relationship between BMI and NYHA functional classiﬁcation.
The statistical analysis included the BMI, NYHA class and its interaction
term (BMI × NYHA class) as independent predictors of the dependent
variables associated with the plasma BNP levels adjusted by age
(p b 0.05). And as a result, in the comparison between NYHA class I and
class II, and in the comparison between NYHA class I and class III
+ IV, each independent parameter was statistically signiﬁcant (both at
p b 0.001), although there was no statistically signiﬁcant difference be-
tween NYHA class II and class III + IV (p = 0.476). This suggests that
the relationship between the plasma BNP level and BMI is modiﬁed by
the NYHA class. In other words, the linear regression lines would differ
in the collinearity between NYHA class I and class II and between NYHA
class I and class III + IV (Fig. 2).
3.6. The distribution patterns of obese and non-obese patients according to
the plasma BNP level
As shown in Fig. 2, the linear regression lines became steeper for the
higher NYHA functional classiﬁcations; however, it is noteworthy that
the plasma BNP levels were still low in the patients with high BMI
even when they had NYHA class III + IV disease.
In order to conﬁrm that there were only a few patients with high
BMI who showed high plasma BNP levels, the distribution patterns of
the study population were examined by dividing patients into two
groups, those who were obese (BMI ≥ 25) and those who were not
(BMI b 25) as shown in Fig. 3. Only 14.0% of the obese group had a plas-
ma BNP level over 1000 pg/mL, so the rate of a high BNP level was sig-
niﬁcantly different between obese and non-obese subjects (p b 0.001).
There were also signiﬁcant differences between the obese group and
the non-obese group in terms of the numbers of patients with BNP
levels of 18.5–40, 40.1–100, 100.1–200 and 200.1–1000 pg/mL. Howev-
er, there was no signiﬁcant difference (p= 0.186) between the obese
(55.2%) and the non-obese patients (44.8%) in terms of the patients
with a BNP value b18.4 pg/mL.
3.7. Kaplan–Meier curves, log-rank test and Cox proportional hazard
models for MACE
We next investigated the clinical outcome by generating Kaplan–
Meier curves for the MACE (Fig. 4A–D). Patients with BMI values
b23.7 kg/m2 (median value) (n = 338, median and IQR of plasma
BNP level, 66.5 [26.1–361.9] pg/mL) had a worse outcome than those
with a value ≥23.7 kg/m2 (n = 338, median and IQR of plasma BNP
level, 34.7 [15.3–129.0] pg/mL) in theMACE-free survival curve [hazard
ratio (HR), 1.986; 95% CI, 1.171–3.367; p= 0.011, Fig. 4A]. In addition,
patients with plasma BNP values ≥200 pg/mL (n = 173, median and
IQR, 586.8 [361.4–1184.9] pg/mL) had a worse outcome than those
with values b200 pg/mL (n = 503, median and IQR, 30.8 [14.3–66.3]
pg/mL) in the MACE-free survival curve (HR, 3.075; 95% CI, 1.856–
5.093; p b 0.001, Fig. 4B). Non-obese patients (BMI b 23.7 kg/m2) with
plasma BNP values ≥200 pg/mL (n = 106, median and IQR, 663.1
[393.3–1429.5] pg/mL) had a worse outcome than those with values
b200 pg/mL (n = 232, median and IQR, 39.4 [17.9–67.7] pg/mL) in
the MACE-free survival curves (HR, 2.509; 95% CI, 1.350–4.662; p =
0.004, Fig. 4C). Obese patients (BMI ≥ 23.7 kg/m2) with plasma BNP
values ≥200 pg/mL (n = 67, median and IQR, 490.3 [295.5–965.1]
pg/mL) also had a worse outcome than those with values b200 pg/mL
(n = 271, median and IQR, 25.0 [12.2–58.4] pg/mL) in the MACE-free
survival curves (HR, 5.911; 95% CI, 2.339–14.936; p b 0.001, Fig. 4D).
4. Discussion
The patterns of distribution of the plasma BNP levels were ﬁrst ex-
amined according to BMI.When the total study population was divided
into two, three or four groups based on BMI, not only the Mann–Whit-
ney U test but also the F test showed statistically signiﬁcant differences
Fig. 1.Distributions of the log BNP levels in each BMI group. These histograms show the distributions of the logarithmic BNP levels (log BNP) in each BMI group (bipartite grouping). The
ﬁtted normal distribution curves andmedian values (colored center lines) of each BMI group are represented on the down side of the panels. Each colored line or curve distinguishes the
BMI levels as follows: red, “BMI = 15.2–23.6 kg/m2” and blue, “BMI = 23.7–40.8 kg/m2”. Each BMI group and the number of patients in each group are explained in each panel, and
the results of the statistical analyses (F, F test; and U, Mann–Whitney's U test) are shown in each panel. Log BNP: logarithmic B-type natriuretic peptide.
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tite group only, Fig. 1). These results indicate not only that the median
levels of plasma BNP shifted to the left (to the lower levels), but also
that the breadth of the distribution became narrower when the BMI be-
came higher. In addition, a negative relationship between the plasmaFig. 2. The relationship between the plasma BNP level and BMI in eachNYHA classiﬁcation. The
in the ﬁgures: A, NYHA class I; B, NYHA class II; C, NYHA class III + IV, and each solid red line
coefﬁcients, respectively). #, p values show the statistical contributions of the NYHA classiﬁc
multiple regression analysis of the inﬂuence of the NYHA functional classiﬁcation. The depen
classiﬁcation, and the interaction term between BMI and NYHA classiﬁcation (BMI × NYHA claBNP levels and BMI was shown for every NYHA classiﬁcation (Fig. 2),
and the regression line was ﬂat, showing a very weak correlation, for
the overall patients (see Results), but it became steeper for patients
with higher NYHA classiﬁcations. This result indicates that the inﬂuence
of the BMI on the plasma BNP levels became stronger as the heart failureplasma BNP level and BMI values in eachNHYA class group are represented as scatter plots
indicates the regression curve for the logarithmic ﬁtted equation (Pearson's correlation
ation to the relationship between the BMI and the plasma BNP level as determined by a
dent variable was the plasma BNP levels, and the explanatory variables were BMI, NYHA
ssiﬁcation). BMI, body mass index; BNP, B-type natriuretic peptide.
Fig. 3. The distribution (%) of patients according to the BNP values in two groups divided by BMI (cut-off set at 25 kg/m2). The distribution of patients in the obese group (BMI≥ 25, solid
bar) and the non-obese group (BMI b 25, open bar). These groups were divided into six groups based on the plasma BNP levels: ≤18.4, 18.5–40, 40.1–100, 100.1–200, 200.1–1000,
N1000 pg/mL. BMI, body mass index; BNP, B-type natriuretic peptide.
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low in patients with a higher BMI, even in cases with severe heart fail-
ure. A typical schematic distribution of the plasma BNP levels according
to the BMI values is shown in Fig. 5A and B. This was also used for the
distribution of patients according to the plasma BNP values in two
sub-groups divided by the BMI (cut-off set at 25 kg/m2, which is the
Japanese clinical diagnostic criteria of obesity). The obese patients
(BMI≥ 25) exhibited gradual reductionswith the increase in their plas-
ma BNP levels based on the plasma BNP level, as noted in the clinical di-
agnostic criteria announced by the Japanese Heart Failure Society
(Fig. 3).
Themechanism underlying the decrease (or lack of elevation) in the
plasma BNP levels in obese patients is unclear at present. Nonetheless,
there was a report showing that the BNP production in the heart was
decreased by insulin resistance in obese patients [30]. Other studies
have indicated that the neutral endopeptidase (NEP) activity and clear-
ance (C)-receptors (NPR-C) were increased in the adipose tissue of
obese patients [19,31]. Thus, the lower production andhigher consump-
tion of the plasma BNP in obese patients would result in lower plasma
BNP levels in these patients.
Natriuretic peptides (NPs: A-type natriuretic peptides and BNP)
have an important additional role in the regulation of metabolism and
energy expenditure [32]. The NPs have also been demonstrated to in-
duce lipolysis in human adipose tissue by using the involved a cGMP-
dependent pathway [33,34]. Emerging evidence that NPs are expressed
in adipose tissue, and that the circulating levels of these peptides are de-
creased in obese patients, may imply that NPs are also involved in the
regulation of energy metabolism [31–34]. The NPs were demonstrated
to directly affect adipose tissue by stimulating lipolysis [33,35]. The
sympathetic nervous system also concomitantly regulated this lipolysis
[36,37]. These NPs (cGMP-dependent pathway) and the sympathetic
nervous system modulate the regulation of adipocyte metabolism and
lead to themanipulation of the NP pathway to increase energy expendi-
ture in obese subjects, which might be beneﬁcial for the complications
of cardiometabolic diseases in obese subjects [34,38,39]. This higher
consumption of plasma BNP was one of the reasons why the median
value and distribution of plasma BNP levels were lower and narrower
in obese patients.
It iswell known that BNP is synthesized in the heart, and that plasma
levels increase in parallel with cardiac dysfunction [21] and this is favor-
able to the failing heart. Thus,when the intrinsic response of BNP is sup-
pressed for some reason, a disruption of the hormone balance would
occur in patients with heart failure. The heart failure would then theo-
retically become exacerbated. In the real world, however, a furthercomplicating matter has been reported. This is the obesity paradox,
where obese patients with heart failure had a better prognosis than
non-obese patients [22–24]. The complex relationships among obesity,
the prognosis and the BNP levels are still unclear. There may be some
unknown key molecule or mechanism that abrogates the disadvantage
that should be associated with low BNP response in obese patients. Low
plasmaBNP levelswould consequently be highly correlatedwith a good
prognosis, regardless of the BMI. This suggests that BNP is still clinically
useful as a marker of heart failure, but that different cut-off levels may
be necessary depending on the BMI of the patient.
If the level of obesity is severe, the plasma BNP level would be an ex-
tremely low value. The mechanism underlying the low plasma BNP
level in obese patients might be lower production and higher consump-
tion of plasma BNP handlings. However, the causality is currently un-
clear, and a low plasma BNP level might instead lead to obesity,
because BNP enhances the metabolism (BNP-induced lipolysis) of fat
cells. Bothmechanismsmay occur, with low BNP and obesity further in-
creasing each other in a cycle [31–35]. However in the patients with
heart failure who had high BMI values, some favorable mechanisms
(e.g., increased energy storage, etc.) had a more important impact on
the prognosis of the heart failure, andwere thus associatedwith a better
outcome. Consequently, low plasma BNP levels were correlated with a
good prognosis, regardless of the BMI, in these patients.
5. Limitations
There are several limitations associated with this study. First, the
percentage of NHYA class I stage heart failure patients was high, com-
prising 78.8% of the study population. Therefore, themoderate or severe
heart failure patients comprised only 19.2% of all patients. It might be
necessary to investigate a more severe heart failure patient population
in a future study. However, although the number of heart failure cases
in this study may seem to be relatively small, it was not a study focused
only on heart failure patients. Thiswas becausewe investigated the gen-
eral distribution of plasma BNP levels in the patients admitted to the
cardiovascular unit in our hospital. When the patients were divided
equally into three groups according to their BMI, the severity of the
heart failure (NYHA classiﬁcation) was distributed in approximately
the same percentages in each group, and the proportion and sample
size of heart failure patients in this studywere appropriate for the statis-
tical analysis.
Second, since these target patients had been admitted to the cardiol-
ogy unit in our hospital, they were not healthy individuals. Therefore,
our ﬁndings would likely be different from those of studies including
Fig. 4. The Kaplan–Meier curves and results of the log-rank test and the Cox proportional hazardmodels for MACE in each BMI and plasma BNP group. The Kaplan–Meier curves show the
event-free survival rates during the long-term follow-up after discharge from the hospital. These patients were divided into groups by BMI or plasma BNP level; A, bipartite grouping (low
BMI, 15.2–23.6 kg/m2, blue line and high BMI, 23.7–40.8 kg/m2, red line); B, divided by the plasma BNP level (cut-off 200 pg/mL) at admission; C or D, divided by the plasma BNP level
(more or less than 200 pg/mL, blue and red lines, respectively) at admission in the lowBMI group (BMI 15.2–23.6) (C) or highBMI group (BMI 23.7–40.8) (D). The Cox proportional hazard
models show the ﬁndings for each group after adjusting for other prognostic parameters (gender, age and renal function). BMI, bodymass index; BNP, B-type natriuretic peptide; MACE,
major adverse cardiovascular event.
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ﬁndings to the normal population might also need to be determined
in another series of studies.
Finally, in the investigation of the clinical outcome by Kaplan–Meier
curves for theMACE, it was difﬁcult to collect all of the data from the pa-
tients for the long-term follow-up, especially since this was a retrospec-
tive cohort study. Some patients (8.8%) had moved from our hospitalarea to another area, so they dropped out from our follow-up as
outpatients.
6. Conclusion
The impact of the BMI on the plasma BNP levels became stronger as
the extent of heart failure becamemore severe. Care should be taken not
Fig. 5. A schematic diagram showing the distribution of the plasma BNP levels according to BMI values in patients with heart failure. A, For the patterns of distribution of the plasma BNP
levels, not onlywere the average levels of the plasma BNP shifted to the left (to lower levels), but the breadth of the distribution became narrowerwhen the BMI increased (changing from
blue line to red line). The distributions of the plasma BNP levels in patients with lower (blue line) and higher (red line) BNP levels were not uniform (see lower panel). B, The relationship
between the BMI and the plasma BNP levels became stronger in patientswith severe heart failure. However, the plasma BNP levels remained low in high BMI patients evenwhen they had
severe heart failure.
45S. Arase et al. / IJC Metabolic & Endocrine 4 (2014) 39–46to underestimate the severity of heart failure in obese patients when
using the plasma BNP levels as a marker of heart failure.
Funding sources
No funding was associated with this study.
Conﬂict of interest
None of the authors has any conﬂict of interest to disclose.
Acknowledgments
We thank all trial physicians and nurses in all participating hospitals
for their important contributions to the study. We also thank Dr. Brian
Quinn (Japan Medical Communication) for his kind advice on the
English language use in this paper.
References
[1] Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine
brain. Nature 1988;332:78–81.
[2] Kangawa K, Tawaragi Y, Oikawa S, Mizuno A, Sakuragawa Y, Nakazato H, et al. Iden-
tiﬁcation of rat gamma atrial natriuretic polypeptide and characterization of the
cDNA encoding its precursor. Nature 1984;312:152–5.
[3] de Bold AJ. Arterial natriuretic factor: a hormone produced by the heart. Science
1985;230:767–70.
[4] Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic
peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natri-
uretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin
Invest 1991;87:1402–12.
[5] Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localiza-
tion and mechanism of secretion of B-type natriuretic peptide in comparison with
those of A-type natriuretic peptide in normal subjects and patients with heart fail-
ure. Circulation 1994;90:195–203.
[6] Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, et al. Inhibi-
tory effect of natriuretic peptides on aldosterone synthase gene expression in cul-
tured neonatal rat cardiocytes. Circulation 2003;107:807–10.[7] Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al.
Increased plasma levels of brain natriuretic peptide inpatientswith acutemyocardial
infarction. Circulation 1993;88:82–91.
[8] Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma
brain natriuretic peptide as an indicator of left ventricular systolic function
and long-term survival after acute myocardial infarction. Comparison with
plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.
Circulation 1996;93:1963–9.
[9] Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of
compensation of endogenous cardiac natriuretic peptide system in chronic heart
failure: prognostic role of plasma brain natriuretic peptide concentration in patients
with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509–16.
[10] Berger R, HuelsmanM, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natriuretic
peptide predicts sudden death in patients with chronic heart failure. Circulation
2002;105:2392–7.
[11] Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in
brain natriuretic peptide and norepinephrine over time andmortality andmorbidity
in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278–83.
[12] Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al.
B-type natriuretic peptides and ejection fraction for prognosis after myocardial
infarction. Circulation 2003;107:2786–92.
[13] Suzuki S, YoshimuraM, NakayamaM, Mizuno Y, Harada E, Ito T, et al. Plasma level of
B-type natriuretic peptide as a prognostic marker after acute myocardial infarction:
a long-term follow-up analysis. Circulation 2004;110:1387–91.
[14] Wang TJ, LarsonMG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic
peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;
350:655–63.
[15] Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al.
B-type natriuretic peptides and cardiovascular risk: systematic review and
meta-analysis of 40 prospective studies. Circulation 2009;120:2177–87.
[16] Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic peptide for the prediction
of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J Heart
Fail 2009;11:958–66.
[17] Daniels LB, Clopton P, Jiang K, Greenberg B, Maisel AS. Prognosis of stage A or B heart
failure patients with elevated B-type natriuretic peptide levels. J Card Fail 2010;16:
93–8.
[18] Kawai M, Yoshimura M, Harada M, Mizuno Y, Hiramitsu S, Shimizu M, et al. Deter-
mination of the B-type natriuretic peptide level as a criterion for abnormalities in
Japanese individuals in routine clinical practice: the J-ABS Multi-center Study
(Japan abnormal BNP standard). Intern Med 2013;52:171–7.
[19] Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, et al. Impact of
obesity on plasma natriuretic peptide levels. Circulation 2004;109:594–600.
[20] Nakane T, Kawai M, Komukai K, Kayama Y, Matsuo S, Nagoshi T, et al. Contribution
of extracardiac factors to the inconsistency between plasma b-type natriuretic pep-
tide levels and the severity of pulmonary congestion on chest x-rays in the diagnosis
of heart failure. Intern Med 2012;51:239–48.
46 S. Arase et al. / IJC Metabolic & Endocrine 4 (2014) 39–46[21] Ito K, Kawai M, Nakane T, Narui R, Hioki M, Tanigawa S, et al. Serial measurements
associated with an amelioration of acute heart failure: an analysis of repeated quan-
tiﬁcation of plasma BNP levels. Eur Heart J Acute Cardiovasc Care 2012;1:240–7.
[22] Lavie CJ, Osman AF, Milani RV, MehraMR. Body composition and prognosis in chron-
ic systolic heart failure: the obesity paradox. Am J Cardiol 2003;91:891–4.
[23] Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity para-
dox: body mass index and outcomes in patients with heart failure. Arch Intern Med
2005;165:55–61.
[24] Komukai K, Minai K, Arase S, Ogawa T, Nakane T, Nagoshi T, et al. Impact of body
mass index on clinical outcome in patients hospitalized with congestive heart fail-
ure. Circ J 2012;76:145–51.
[25] Hunt SA, AbrahamWT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. focused
update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Man-
agement of Heart Failure in Adults: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines: devel-
oped in collaboration with the International Society for Heart and Lung Transplanta-
tion. Circulation 2009;119:e391–479 [http://circ.ahajournals.org/cgi/reprint/
CIRCULATIONAHA.109.192065].
[26] Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA,
et al. ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis
and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis
and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Car-
diology. Developed in collaborationwith theHeart Failure Association of the ESC (HFA)
and endorsed by the European Society of Intensive CareMedicine (ESICM). Eur Heart J
2008;29:2388–442 [http://www.escardio.org/guidelines-surveys/esc-guidelines/Doc-
uments/CHF/guidelines-HF-FT.pdf].
[27] Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, RothD. Amore accuratemethod to es-
timate glomerular ﬁltration rate from serum creatinine: a new prediction equation.
Modiﬁcation of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.
[28] Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators develop-
ing the Japanese equation for estimated GFR. Revised equations for estimated GFR
from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–92.[29] Inoue T, Kawai M, Nakane T, Nojiri A, Minai K, Komukai K, et al. Inﬂuence of low-
grade inﬂammation on plasma B-type natriuretic peptide levels. Intern Med 2010;
49:2659–68.
[30] Mizuno Y, Harada E, Katoh D, Kashiwagi Y, Morikawa Y, Nakagawa H, et al. Cardiac
production of B-type natriuretic peptide is inversely related to the plasma level of
free fatty acids in obese individuals— possible involvement of the insulin resistance.
Endocr J 2013;60:87–95.
[31] Date T, Yamane T, Yamashita S, Matsuo S, Matsushima M, Inada K, et al. Paradoxical
clearance of natriuretic peptide between pulmonary and systemic circulation: a pul-
monary mechanism of maintaining natriuretic peptide plasma concentration in
obese individuals. J Clin Endocrinol Metab 2012;97:E14–21.
[32] Moro C, Lafontan M. Natriuretic peptides and cGMP signaling control of energy ho-
meostasis. Am J Physiol Heart Circ Physiol 2013;304:H358–68.
[33] Sarzani R, Dessì-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic
peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996;19:
581–5.
[34] Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessì-Fulgheri P, Zhang C, et al. Cardiac na-
triuretic peptides act via p38MAPK to induce the brown fat thermogenic program in
mouse and human adipocytes. J Clin Invest 2012;122:1022–36.
[35] Sengenès C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumié A, Lafontan M, et al.
Natriuretic peptide-dependent lipolysis in fat cells is a primate speciﬁcity. Am J
Physiol Regul Integr Comp Physiol 2002;283:R257–65.
[36] Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a
new lipolytic pathway in human adipocytes. FASEB J 2000;14:1345–51.
[37] Collins S. A heart-adipose tissue connection in the regulation of energy metabolism.
Nat Rev Endocrinol 2014;10:157–63.
[38] Birkenfeld AL, Budziarek P, Boschmann M, Moro C, Adams F, Franke G, et al. Atrial
natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes 2008;
57:3199–204.
[39] Polak J, Kotrc M,Wedellova Z, Jabor A, Malek I, Kautzner J, et al. Lipolytic effects of B-
type natriuretic peptide 1–32 in adipose tissue of heart failure patients compared
with healthy controls. J Am Coll Cardiol 2011;58:1119–25.
